



LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
Pharmacy Affairs

August 10th, 2022

TO: MHLA Clinics
FROM: DHS Pharmacy Affairs
RE: DHS MHLA Formulary Update

MY HEALTH LA FORMULARY

Due to recent 340B distribution restrictions placed by Merck and Bausch Health, multiple MHLA formulary products will be restricted or removed. **The formulary amendments outlined below will go into effect immediately.** We appreciate your efforts to ensure MHLA participants' continuity of care and strongly encourage MHLA Clinics to proactively work with your 340B contract pharmacies as we navigate through these manufacturer-mandated 340B distribution restrictions.

UPDATE – Formulary Amendment (effective August 10th, 2022)

Drug Product	Comments
Januvia® 25mg, 50mg and 100mg oral tablets	<p>Januvia® claims will reject at <u>contract 340B pharmacies</u> with the message: “Not cvd. Consider Tradjenta or call CCT”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none">• <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options, including <u>Tradjenta®</u>.• <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options, including <u>Tradjenta®</u>. <p><u>NOTE:</u> Merck’s distribution restrictions does NOT apply to On-Site Pharmacies and Dispensaries. Januvia® will continue to process according to prior formulary restrictions at these locations.</p>

This document contains confidential information intended for MHLA Program Healthcare Providers and Professionals. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.

Example Bausch Health products listed below. NOTE: This is not a complete list.

Ativan®
Cardizem®
Cardizem CD®
Diltiazem HCl
Diltiazem HCl ER Coated Beads
Enalapril Maleate
Isordil®
Metronidazole
Mysoline®
Nifedipine ER
Nifedipine ER Osmotic Release
Pepcid®
Vaseretic®
Vasotec®
Zovirax®

Claims for Bausch Health products will reject at contract 340B pharmacies with the message: **“Use alt NDC. Bausch products not covered”**

If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:

- **Has an On-Site Pharmacy or Dispensary:** CCT will advise you to try billing an equivalent generic from another manufacturer. If that is not an option, please direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy, please contact the prescriber for alternative formulary options.
- **Does NOT have an On-site Pharmacy or Dispensary:** CCT will advise you to try billing an equivalent generic alternative from another manufacturer. If that is not an option, please contact the prescriber for alternative formulary options.

NOTE: Bausch’s distribution restrictions **does NOT apply to On-Site Pharmacies and Dispensaries**. Bausch products will continue to process according to prior formulary restrictions at these locations.